

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/681,773	
	Filing Date	October 7, 2003	
	First Named Inventor	Hajime Matsuzaki	
	Art Unit	Unknown	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	5	Attorney Docket Number	3522.2

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Substitute for Form 1449A (2 pages); - References (17); and - Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Sandra E. Wells 52,349
Signature	<i>Sandra E. Wells</i>
Date	3/17/04

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Leticia R. Block		
Signature	<i>Leticia R. Block</i>	Date	3-18-2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT
Attorney Docket No. 3522.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hajime Matsuzaki, et al.
Serial No: 10/681,773
Filing Date: October 7, 2003
Title: Methods for Genotyping
Polymorphisms in Humans

Examiner: TBD

Group Art Unit: TBD

INFORMATION DISCLOSURE
STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR § 1.56, § 1.97 and § 1.98, the documents listed on the accompanying U.S. Patent & Trademark Office's Modified Form-1449 are called to the attention of the Examiner for consideration in connection with the above-identified patent application.

Citation of these documents shall not be construed as (1) an admission that the documents are necessarily prior art with respect to the instant invention; (2) a representation that a search has been made; or (3) an admission that the information cited herein is, or is considered to be, material to patentability in any way, including that as defined in § 1.56(b).


The Commissioner is hereby authorized to charge the required fees to Account No. 01-0431 in order to have this Information Disclosure Statement considered.


Respectfully submitted,

Dated: 3/17/04

Customer No. 22886
Legal Department
Affymetrix, Inc.
3380 Central Expressway
Santa Clara, CA 95051
Tel: (408) 731-5000/Fax (408) 731-5392

Sandra E. Wells
Reg. No. 52,349


Reg. No.: 52,349



PTO/SB/08b(08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/681,773
Filing Date	October 7, 2003
First Named Inventor	Hajime Matsuzaki
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	3522.2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	CARRASQUILLO, MINERVA M., ET AL., Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease, Nature Genetics, October 2002, pages 237-44, Vol. 32, Nature Publishing Group, New York, NY, USA.	
	2	DALMA-WEISZHAUSZ, DENNISE D., ET AL., Single nucleotide polymorphisms and their characterization with oligonucleotide microarrays, Psychiatric Genetics, 2002, pages 97-107, Vol. 12, No. 2, Lippincott Williams & Wilkins, Philadelphia, PA, USA.	
	3	DONG, SHOULIAN, ET AL., Flexible Use of High-Density Oligonucleotide Arrays for Single-Nucleotide Polymorphism Discovery and Validation, Genome Research, 2001, pages 1418-24, Vol. 11, Cold Spring Harbor Laboratory Press, USA.	
	4	DUMUR, CATHERINE I., ET AL., Genome-wide detection of LOH in prostate cancer using human SNP microarray technology, Genomics, 2003, pages 260-69, Vol. 81, Academic Press, USA.	
	5	FAN, JIAN-BING, ET AL., Paternal Origins of Complete Hydatidiform Moles Proven by Whole Genome Single-Nucleotide Polymorphism Haplotyping, Genomics, January 2002, pages 58-62, Vol. 79, No. 1, Academic Press, USA.	
	6	GARCIA, CHRISTINE KIM, ET AL., Sequence Diversity in Genes of Lipid Metabolism, Genome Research, 2001, pages 1043-52, Vol. 11, Cold Spring Harbor Laboratory Press, USA.	
	7	GUO, QINGBIN M., DNA Microarray and cancer, Current Opinion in Oncology, 2003, pages 36-43, Vol. 15, Lippincott Williams & Wilkins, Philadelphia, PA, USA.	
	8	HALUSHKA, MARC K., ET AL., Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis, Nature Genetics, July 1999, pages 239-47, Vol. 22, Nature America, Inc., USA.	
	9	LINDBLAD-TOH, KERSTIN, ET AL., Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays, Nature Biotechnology, September 2000, pages 1001-05, Vol. 18, Nature Publishing Group, New York, NY, USA.	
	10	LINDBLAD-TOH, KERSTIN, ET AL., Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse, Nature Genetics, April 2000, pages 381-86, Vol. 24, Nature America, Inc., USA.	
	11	LINDROOS, KATARINA, ET AL., Minisequencing on oligonucleotide microarrays: comparison of immobilisation chemistries, Nucleic Acids Research, 2001, pages e69 (1-7), Vol. 29, No. 13, Oxford University Press, UK.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/681,773
Filing Date	October 7, 2003
First Named Inventor	Hajime Matsuzaki
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	3522.2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	MEI, RUI, ET AL., Genome-wide Detection of Allelic Imbalance Using Human SNPs and High-density DNA Arrays, Genome Research, 2000, pages 1126-37, Vol. 10, No. 8, Cold Spring Harbor Laboratory Press, USA.	
	13	SCHUBERT, ELIZABETH L., ET AL., Single Nucleotide Polymorphism Array Analysis of Flow-Sorted Epithelial Cells from Frozen Versus Fixed Tissues for Whole Genome Analysis of Allelic Loss in Breast Cancer, American Journal of Pathology, January 2002, pages 73-79, Vol. 160, No. 1, American Society for Investigative Pathology, USA.	
	14	WARRINGTON, JANET A., ET AL., New Developments in High-Throughput Resequencing and Variation Detection Using High Density Microarrays, Human Mutation, 2002, pages 402-09, Vol. 19, No. 4, Wiley-Liss, Inc., USA.	
	15	WILSON, S.G., ET AL., Comparison of Genome Screens for Two Independent Cohorts Provides Replication of Suggestive Linkage of Bone Mineral Density to 3p21 and 1p36, American Journal of Human Genetics, 2003, pages 144-55, Vol. 72, No. 1, American Society of Human Genetics, USA.	
	16	ZHOU, WEI, Mapping genetic alterations in tumors with single nucleotide polymorphisms, Current Opinion in Oncology, 2003, pages 50-54, Vol. 15, No. 1, Lippincott Williams & Wilkins, Inc, Philadelphia, PA, USA.	
	17	RUBENSTEIN, K, The Current State of the Biochip Business, Drug & Market Development, November 1999, pages 392-96, Vol. 10, No. 11, Drug & Market Development Publications, USA.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.